Why is Syncom Formulations (India) Ltd falling/rising?

Recent Price Movement and Market Context

Syncom Formulations has outperformed its sector and benchmark indices in the short term, with a one-week return of 12.08% compared to the Sensex’s decline of 1.00%. This surge follows four consecutive days of gains, accumulating a 13.22% return over this period. The stock’s current price is above its 5-day and 20-day moving averages, signalling short-term strength, although it remains below longer-term averages such as the 50-day, 100-day, and 200-day, indicating some caution among investors regarding sustained momentum.

Liquidity remains adequate for trading, with the stock’s daily traded value supporting transactions up to ₹0.04 crore. However, investor participation has slightly waned, as delivery volumes on 30 January fell by 3.42% compared to the five-day average, suggesting some hesitation despite the price rally.

Strong Financial Performance Driving Confidence

The recent upward movement in Syncom’s stock price is largely supported by its very positive financial results declared in September 2025. The company has reported growth in operating profit by 8.29%, marking the sixth consecutive quarter of positive results. Over the latest six months, the company’s profit after tax (PAT) surged by 72.46% to ₹32.32 crore, while net sales increased by 25.87% to ₹238.62 crore. These figures underscore a significant improvement in operational efficiency and revenue generation.

Additionally, Syncom boasts a high return on capital employed (ROCE) of 22.06% for the half-year period, reflecting effective utilisation of capital. Its return on equity (ROE) stands at a respectable 16.6%, and the stock trades at a price-to-book value of 3.3, indicating a fair valuation relative to its peers. Despite the stock’s negative one-year return of -23.80%, the company’s profits have grown by 90.1% over the same period, resulting in a low PEG ratio of 0.2, which may appeal to value-oriented investors.

Long-Term Challenges Temper Optimism

While the short-term outlook appears encouraging, Syncom’s long-term growth trajectory presents concerns. Over the past five years, net sales have declined at an annualised rate of 63.63%, and operating profit has contracted by 52.27%. This stark contrast between recent quarterly improvements and prolonged historical underperformance may explain the cautious stance of some market participants.

Moreover, the company’s limited presence in domestic mutual fund portfolios—holding effectively zero percent—raises questions about institutional confidence. Mutual funds typically conduct thorough due diligence and their minimal stake could indicate reservations about the company’s valuation or business prospects.

Syncom’s underperformance relative to the broader market is also notable. While the BSE500 index has delivered a 5.79% return over the last year, Syncom’s shares have declined by 23.80%, highlighting the stock’s struggle to keep pace with market gains despite recent profit growth.

Conclusion: A Stock in Transition

Syncom Formulations’ recent price rise on 01-Feb reflects a market response to its improved quarterly earnings and positive short-term momentum. The company’s strong half-year financials, including significant profit growth and solid returns on capital, have helped the stock outperform its sector and benchmark indices in the near term. However, persistent long-term sales decline and muted institutional interest temper enthusiasm, suggesting that investors remain cautious about the sustainability of this rally.

For investors, the stock presents a mixed picture: attractive short-term gains backed by improving fundamentals, yet shadowed by historical underperformance and limited mutual fund endorsement. Careful monitoring of future quarterly results and broader market sentiment will be essential to assess whether Syncom can maintain its upward trajectory or if the longer-term challenges will continue to weigh on its valuation.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →